The exon 19-deleted EGFR undergoes ubiquitylation-mediated endocytic degradation via dynamin activity-dependent and -independent mechanisms

Abstract

BackgroundThe epidermal growth factor receptor (EGFR) is closely implicated in cancer, and sequencing analyses have revealed a high mutation rate of EGFR in lung cancer. Recent advances have provided novel insights into the endocytic regulation of wild-type EGFR, but that of mutated EGFR remains elusive. In the present study, we aim to investigate the endocytic degradation of a frequently occurred exon 19-deleted mutant in lung cancer.MethodsThe EGF-induced endocytic degradation of EGFR was examined in a panel of lung cancer cells using immunoblotting. The subcellular distribution of internalized EGFR was investigated using immunofluorescence and confocal microscopy. The effects of dynamin were assessed using its small molecule inhibitors, while the influence of RTN3 was tested using shRNA-mediated knockdown. Finally the ubiquitylation status of EGFR mutant was studied using immunoprecipitation under steady state and tyrosine kinase inhibitor-treated conditions.ResultsEGF induced various rates of EGFR endocytic degradation in lung cancer cells. Interestingly, the exon 19 deletion mutant is constantly internalized and sorted to lysosome for degradation, and this process is independent of dynamin activity. EGF stimulation and HSP90 inhibition further enhance the endocytic degradation of the exon 19 deletion mutant, in a dynamin activity-dependent and -independent manner, respectively. Albeit with different modes of internalization, the uptake of the exon 19-deleted EGFR is mediated through receptor ubiquitylation.ConclusionsThe internalized EGFR mutant is constantly routed through endosome to lysosome for degradation. The endocytosis of EGFR mutant occurs through both dynamin activity-dependent and -independent mechanisms. Our findings gain novel insights into the endocytic regulation of mutated EGFR and may have potential clinical implications.

Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects

“…Immunofluorescence was performed as previously described [ 24 ]. Cells were seeded onto glass coverslips and cultured in 6-well plates.…”

USP29 enhances chemotherapy-induced stemness in non-small cell lung cancer via stabilizing Snail1 in response to oxidative stress

“…To prepare protein lysates, treated cells were PBS washed and lysed using the "RIPA" buffer as previously described 31 . Protein samples were spun at 13, 000 rpm in a chilled benchtop centrifuge (Eppendorf) to remove particulates.…”

DRAM1 plays a tumor suppressor role in NSCLC cells by promoting lysosomal degradation of EGFR

“…Mutant EGFRs are preferentially trafficked into the endocytic recycling compartments (ERC), allowing them to go back to the plasma membrane or to interact with Src. Exon-19-deleted EGFR is colocalized with endocytic compartments under steady-state conditions, indicating that the exon-19-deleted EGFR mutant is constantly internalized and sorted to lysosomes for degradation 5 . It has been reported that unliganded EGFR can be internalized at a much slower rate than EGF-stimulated EGFR 37 .…”

“…The mutations of EGFR in NSCLC are concentrated in exons 18–20, encoding the tyrosine kinase domain, and they affect the ATP binding pocket of the tyrosine kinase domain and lead to ligand-independent activation of EGFR. Under a steady state or EGF stimulation, the internalized mutant EGFR travels via the canonical endosome-lysosome route for degradation 5 .…”